Digestive Disease Week

Digestive Disease Week

Disclosures: Panaccione reports consulting for AbbVie, Allergan, Amgen, Arena Pharma, BMS, Celgene, Gilead, Janssen, Lily, Pfizer, Sandoz and Takeda. Please see the study for all other authors’ relevant financial disclosures.
June 02, 2021
1 min watch
Save

VIDEO: Skyrizi offers hope in refractory Crohn's

Disclosures: Panaccione reports consulting for AbbVie, Allergan, Amgen, Arena Pharma, BMS, Celgene, Gilead, Janssen, Lily, Pfizer, Sandoz and Takeda. Please see the study for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Remo Panaccione, MD, University of Calgary, tells Healio Gastroenterology that Skyrizi induced clinical remission and endoscopic response in patients with Crohn’s disease, according to results from the ADVANCE and MOTIVATE trials.